Table 2 Multivariate analysis of clinical factors associated with Progression-Free Survival and Overall Survival among patients with ESCC
Variates | Progression-Free Survival | Overall Survival | ||||
|---|---|---|---|---|---|---|
HR(95%CI) | χ2 | p | HR(95%CI) | χ2 | p | |
gender | 0.746 (0.611–0.910) | 8.375 | 0.004 | 0.755 (0.615–0.926) | 7.275 | 0.007 |
age | 0.997 (0.988–1.006) | 0.511 | 0.475 | 0.997 (0.988–1.006) | 0.470 | 0.493 |
location | 1.162 (1.031–1.308) | 6.095 | 0.014 | 1.131 (1.003–1.275) | 4.023 | 0.045 |
T stage | 1.184 (1.029–1.362) | 5.547 | 0.019 | 1.266 (1.095–1.462) | 10.22 | 0.001 |
N stage | 1.328 (1.013–1.741) | 4.219 | 0.040 | 1.303 (0.993–1.711) | 3.640 | 0.056 |
TNM stage | 1.236 (1.014–1.506) | 4.411 | 0.036 | 1.181 (0.965–1.445) | 2.601 | 0.107 |
RT dose | 0.977 (0.954–1.001) | 3.631 | 0.057 | 0.970 (0.946–0.995) | 5.681 | 0.017 |
Treatment | 0.741 (0.621–0.884) | 11.061 | 0.001 | 0.712 (0.595–0.852) | 13.71 | 0.000 |